Skip to main content
Monday, November 16, 2026Nov 16

Spiegel: Preserving a safety net for needy patients

spiegel-preserving-safety-net-needy-patients
spiegel-preserving-safety-net-needy-patients
photo Kevin M. Spiegel

There is a federal statute – the 340B drug discount program – that helps safety-net hospitals like the Erlanger Health System to purchase medications at discounted pricing for needy patients. And now the Pharmaceutical Research and Manufacturers Association of America is leading an effort to restrict and possibly repeal the 340B program.

President George H.W. Bush and Congress created the 340B drug discount program with bipartisan support more than 20 years ago. The program is not a financial burden on taxpayers because there is no federal funding. The for-profit pharmaceutical industry provides the funds. In fact, the program actually saves taxpayers money because the discounted drugs help keep people healthy through appropriate access to medications. This is significant for public, safety-net hospitals.

Medicines purchased through the program represent only 2 percent of the annual $325 billion U.S. pharmaceutical market – a minuscule amount compared to the patient benefits. And the highly profitable pharmaceutical industry wants to change the rules for providing these discounts to hospitals.

The 340B program allows safety-net hospitals such as Erlanger to purchase medications for eligible patients at discounted pricing. For Erlanger, this means a savings of $9 million annually. Those savings help fund our community-based health services and over $92 million in uncompensated health care.

An example of an Erlanger program which is fully funded by these 340B savings is the pharmacy at the Dodson Avenue Community Health Center.